Hersh Gupta
YOU?
Author Swipe
View article: Supplementary Figure 6 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 6 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 6. (A) Tumor mutational burden and (B) PD-L1 tumor proportion score distributions according to ATM protein expression by IHC (lost versus intact).
View article: Supplementary Table 7 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Table 7 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Table 7. Baseline clinicopathologic features of patients with ATM mutated and ATM wild-type NSCLCs which underwent multiplexed immunofluorescence at the DFCI.
View article: Supplementary Table 4 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Table 4 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Table 4. Baseline clinicopathologic features of patients with ATM mutated NSCLC according ATM protein expression by immunohistochemistry.
View article: Supplementary Figure 14 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 14 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 14. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with advanced/metastatic PD-L1 negative (<1%) NSCLC, according t…
View article: Supplementary Figure 18 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 18 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 18. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with ATMMUT NSCLC, according to STK11 mutation. (D) Objective re…
View article: Supplementary Figure 10 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 10 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 10. (A) Progression-free and (B) overall survival among all patients with stage III NSCLC according to ATM mutation status. (C) Progression-free and (D) overall survival among patients with stage III NSCLC who received…
View article: Supplementary Figure 1. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 1. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 1. (A) ATM mutation classification schema (B) Lollipop plot of all 714 mutations in the ATM gene identified in the combined DFCI/MSK cohort. (C) Lollipop plot of all 152 benign mutations in the ATM gene identified in t…
View article: Supplementary Figure 15 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 15 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 15. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to chemo-immunotherapy among patients with advanced/metastatic PD-L1 negative (<1%) NSCLC, according to ATM mutation status. (D) …
View article: Supplementary Figure 26 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 26 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 26. Proportion of (A) tumor, (B) non-tumor, and (C) total PD-L1+ cells according to ATM/TP53 co-mutation status.
View article: Supplementary Figure 5 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 5 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 5. (A) Median distance of each missense mutation from the closest intron start. (B) Median distance of each missense mutation from the closest intron end. (C) Proportion of cases with ATM loss and ATM intact expression…
View article: Supplementary Figure 9 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 9 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 9. (A) Disease free- and overall survival among patients with (A) stage I, and (B) stage II NSCLC according to ATM mutation status.
View article: Supplementary Figure 20 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 20 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 20. (A) Intratumoral, (B) tumor-stroma interface, and (C) total CD8+ T cells in ATMMUT and ATMWT NSCLCs. (D) Intratumoral, (E) tumor-stroma interface, and (F) total PD1+ immune cells in ATMMUT and ATMWT NSCLCs.
View article: Supplementary Figure 11 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 11 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 11. Overall survival since the date of initial diagnosis among patients with stage IV NSCLC according to ATM mutation status.
View article: Supplementary Figure 24 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 24 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 24. (A) Intratumoral, (B) tumor-stroma interface, and (C) total CD8+ T cells according to ATM/TP53 co-mutation status. (D) Intratumoral, (E) tumor-stroma interface, and (F) total PD1+ immune cells according to ATM/TP53…
View article: Supplementary Figure 28 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 28 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 28. (A) Box-plot showing the distribution of tumor-infiltrating lymphocytes assessed using computational pathology algorithm in ATMMUT and ATMWT NSCLCs. (B) Box-plot showing the distribution of tumor-infiltrating lymph…
View article: Supplementary Figure 12 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 12 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 12. Disease-free survival and overall survival among patients with (A) stage I, (B) stage II, and (C) stage III NSCLC according to ATM expression by immunohistochemistry.
View article: Supplementary Table 3 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Table 3 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Table 3. Baseline clinicopathologic features of patients with ATMMUT and ATMWT NSCLC at the Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.
View article: Supplementary Figure 2 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 2 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 2. Proportion of samples with PD-L1 TPS ≥1%, ≥50%, ≥90% according to ATM mutation status (ATMMUT versus ATMWT).
View article: Supplementary Table 6 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Table 6 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Table 6. Baseline clinicopathologic features of patients with ATM mutated NSCLC according ATM protein expression by immunohistochemistry.
View article: Supplementary Figure 22. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 22. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 22. Proportion of (A) tumor, (B) non-tumor, and (C) total PD-L1+ cells in ATMMUT and ATMWT NSCLCs.
View article: Supplementary Figure 29 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 29 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 29. Box plot showing immune cell subsets significantly enriched among ATMMUT versus ATMWT NSCLC as assessed by deconvoluting bulky RNAseq data from the TCGA-NSCLC dataset. Non-significant results are not shown.
View article: Supplementary Figure 23. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 23. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 23. Correlation of intratumoral, tumor-stroma interface, and total CD8+, PD1+, CD8+PD1+, FOXP3+ T cells and tumoral and non-tumoral PD-L1+ cells among ATMMUT NSCLCs.
View article: Supplementary Table 1 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Table 1 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Table 1. Baseline clinicopathologic features of the 5172 patients with NSCLC which underwent comprehensive tumor genomic profiling at the Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.
View article: Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 16. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition monotherapy among patients with advanced/metastatic NSCLC, according to ATM/TP53 co-mutation status. (D) Ob…
View article: Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2 Open
View article: P223: Discovery of rare disease variants specific to populations using genomic data from diverse populations in All of Us
P223: Discovery of rare disease variants specific to populations using genomic data from diverse populations in All of Us Open
View article: Towards a precision approach to anesthetic/analgesic immunomodulation in cancer
Towards a precision approach to anesthetic/analgesic immunomodulation in cancer Open
Background Immunomodulation is widely invoked to explain possible effects of anesthetic/analgesic drugs on recurrence and survival in cancer patients. By analogy with immune checkpoint inhibitors, which enhance anti-tumor actions of immune…
View article: Supplementary Figure 26 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 26 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 26. Proportion of (A) tumor, (B) non-tumor, and (C) total PD-L1+ cells according to ATM/TP53 co-mutation status.
View article: Supplementary Table 2 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Table 2 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Table 2. List of potential ATM germline variants identified among 3800 patients with NSCLC at the DFCI
View article: Supplementary Table S15 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Supplementary Table S15 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer Open
List Of Germline Variants In Pancreatic Cancer Cohort